US20240024316A1 - Method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing - Google Patents
Method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing Download PDFInfo
- Publication number
- US20240024316A1 US20240024316A1 US18/149,992 US202318149992A US2024024316A1 US 20240024316 A1 US20240024316 A1 US 20240024316A1 US 202318149992 A US202318149992 A US 202318149992A US 2024024316 A1 US2024024316 A1 US 2024024316A1
- Authority
- US
- United States
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- diazaspiro
- pyrimidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 title claims abstract description 69
- 238000000034 method Methods 0.000 title claims abstract description 52
- 150000001875 compounds Chemical class 0.000 claims abstract description 67
- TZSZZENYCISATO-WIOPSUGQSA-N rodatristat Chemical compound CCOC(=O)[C@@H]1CC2(CN1)CCN(CC2)c1cc(O[C@H](c2ccc(Cl)cc2-c2ccccc2)C(F)(F)F)nc(N)n1 TZSZZENYCISATO-WIOPSUGQSA-N 0.000 claims abstract description 34
- 150000003839 salts Chemical class 0.000 claims abstract description 25
- ZNSPHKJFQDEABI-NZQKXSOJSA-N Nc1nc(O[C@H](c2ccc(Cl)cc2-c2ccccc2)C(F)(F)F)cc(n1)N1CCC2(CN[C@@H](C2)C(O)=O)CC1 Chemical compound Nc1nc(O[C@H](c2ccc(Cl)cc2-c2ccccc2)C(F)(F)F)cc(n1)N1CCC2(CN[C@@H](C2)C(O)=O)CC1 ZNSPHKJFQDEABI-NZQKXSOJSA-N 0.000 claims abstract description 19
- 239000003112 inhibitor Substances 0.000 claims abstract description 12
- 101001074035 Homo sapiens Zinc finger protein GLI2 Proteins 0.000 claims abstract description 8
- 102100035558 Zinc finger protein GLI2 Human genes 0.000 claims abstract description 8
- 239000000203 mixture Substances 0.000 claims description 21
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 16
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 2
- 230000001747 exhibiting effect Effects 0.000 claims 1
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 58
- DUUGKQCEGZLZNO-UHFFFAOYSA-N 5-hydroxyindoleacetic acid Chemical compound C1=C(O)C=C2C(CC(=O)O)=CNC2=C1 DUUGKQCEGZLZNO-UHFFFAOYSA-N 0.000 description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 20
- 229940076279 serotonin Drugs 0.000 description 15
- 201000010099 disease Diseases 0.000 description 13
- 101000830742 Homo sapiens Tryptophan 5-hydroxylase 1 Proteins 0.000 description 12
- 102100024971 Tryptophan 5-hydroxylase 1 Human genes 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 9
- 230000009467 reduction Effects 0.000 description 9
- -1 RVT-1201 compound Chemical class 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 7
- 208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical group COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 230000007170 pathology Effects 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 230000002093 peripheral effect Effects 0.000 description 5
- 239000000902 placebo Substances 0.000 description 5
- 229940068196 placebo Drugs 0.000 description 5
- 208000002815 pulmonary hypertension Diseases 0.000 description 5
- 208000019693 Lung disease Diseases 0.000 description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 230000002485 urinary effect Effects 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 208000021124 Heritable pulmonary arterial hypertension Diseases 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- 208000020875 Idiopathic pulmonary arterial hypertension Diseases 0.000 description 3
- 208000014777 Pulmonary venoocclusive disease Diseases 0.000 description 3
- 229940127410 Tryptophan Hydroxylase Inhibitors Drugs 0.000 description 3
- 208000032594 Vascular Remodeling Diseases 0.000 description 3
- 239000000090 biomarker Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 239000008297 liquid dosage form Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000006186 oral dosage form Substances 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- PPDNGMUGVMESGE-JTQLQIEISA-N (2s)-2-amino-3-(4-ethynylphenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(C#C)C=C1 PPDNGMUGVMESGE-JTQLQIEISA-N 0.000 description 2
- HNXQXTQTPAJEJL-UHFFFAOYSA-N 2-aminopteridin-4-ol Chemical compound C1=CN=C2NC(N)=NC(=O)C2=N1 HNXQXTQTPAJEJL-UHFFFAOYSA-N 0.000 description 2
- LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 description 2
- 229940000681 5-hydroxytryptophan Drugs 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 102000003823 Aromatic-L-amino-acid decarboxylases Human genes 0.000 description 2
- 108090000121 Aromatic-L-amino-acid decarboxylases Proteins 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 208000037357 HIV infectious disease Diseases 0.000 description 2
- 101000892398 Homo sapiens Tryptophan 2,3-dioxygenase Proteins 0.000 description 2
- 101000851865 Homo sapiens Tryptophan 5-hydroxylase 2 Proteins 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 206010039710 Scleroderma Diseases 0.000 description 2
- 102100036474 Tryptophan 5-hydroxylase 2 Human genes 0.000 description 2
- 108010031944 Tryptophan Hydroxylase Proteins 0.000 description 2
- 102000005506 Tryptophan Hydroxylase Human genes 0.000 description 2
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 2
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 208000018631 connective tissue disease Diseases 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- LDCYZAJDBXYCGN-UHFFFAOYSA-N oxitriptan Natural products C1=C(O)C=C2C(CC(N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-UHFFFAOYSA-N 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 238000011808 rodent model Methods 0.000 description 2
- FNKQXYHWGSIFBK-RPDRRWSUSA-N sapropterin Chemical compound N1=C(N)NC(=O)C2=C1NC[C@H]([C@@H](O)[C@@H](O)C)N2 FNKQXYHWGSIFBK-RPDRRWSUSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 102000000632 Aromatic amino acid hydroxylases Human genes 0.000 description 1
- 108050008079 Aromatic amino acid hydroxylases Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- HLGAUGMSEMYPBW-UHFFFAOYSA-N C1=CC(CC(N)C(O)=O)=CC=C1C1=NC=NC=N1 Chemical class C1=CC(CC(N)C(O)=O)=CC=C1C1=NC=NC=N1 HLGAUGMSEMYPBW-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 208000029147 Collagen-vascular disease Diseases 0.000 description 1
- 208000002330 Congenital Heart Defects Diseases 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- NIGWMJHCCYYCSF-UHFFFAOYSA-N Fenclonine Chemical compound OC(=O)C(N)CC1=CC=C(Cl)C=C1 NIGWMJHCCYYCSF-UHFFFAOYSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 208000015872 Gaucher disease Diseases 0.000 description 1
- 208000031953 Hereditary hemorrhagic telangiectasia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000014767 Myeloproliferative disease Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010069013 Phenylalanine Hydroxylase Proteins 0.000 description 1
- 102100038223 Phenylalanine-4-hydroxylase Human genes 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 208000031467 Pulmonary capillary hemangiomatosis Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 208000024799 Thyroid disease Diseases 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 229940116984 Tryptophan 5 hydroxylase inhibitor Drugs 0.000 description 1
- 108090000885 Tryptophan 5-monooxygenases Proteins 0.000 description 1
- 102000004271 Tryptophan 5-monooxygenases Human genes 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 229940124301 concurrent medication Drugs 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- QPNKYNYIKKVVQB-UHFFFAOYSA-N crotaleschenine Natural products O1C(=O)C(C)C(C)C(C)(O)C(=O)OCC2=CCN3C2C1CC3 QPNKYNYIKKVVQB-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 208000007345 glycogen storage disease Diseases 0.000 description 1
- 208000034737 hemoglobinopathy Diseases 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000018337 inherited hemoglobinopathy Diseases 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- QVCMHGGNRFRMAD-XFGHUUIASA-N monocrotaline Chemical compound C1OC(=O)[C@](C)(O)[C@@](O)(C)[C@@H](C)C(=O)O[C@@H]2CCN3[C@@H]2C1=CC3 QVCMHGGNRFRMAD-XFGHUUIASA-N 0.000 description 1
- QVCMHGGNRFRMAD-UHFFFAOYSA-N monocrotaline Natural products C1OC(=O)C(C)(O)C(O)(C)C(C)C(=O)OC2CCN3C2C1=CC3 QVCMHGGNRFRMAD-UHFFFAOYSA-N 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000003249 myenteric plexus Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000004560 pineal gland Anatomy 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 208000007232 portal hypertension Diseases 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000008433 psychological processes and functions Effects 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 210000003492 pulmonary vein Anatomy 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000010911 splenectomy Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Definitions
- the present disclosure relates to a method for treating pulmonary arterial hypertension (PAH) and associated pulmonary arterial hypertension (APAH) in a patient.
- PAH pulmonary arterial hypertension
- APAH pulmonary arterial hypertension
- the present disclosure further relates to a method for treating PAH/APAH via a systemic administration to a patient.
- the present disclosure yet further relates to a method for treating PAH/APAH in a patient with a single daily dose.
- Pulmonary arterial hypertension is one form of a broader condition known as pulmonary hypertension, which means high blood pressure in the lungs.
- PAH Pulmonary arterial hypertension
- increased pressure in the vessels is caused by obstruction in small arteries in the lungs and/or constriction or narrowing in diameter, which increases the resistance to blood flow through the lungs. Over time, the increased blood pressure can damage the heart.
- the cause is unknown. Others causes can be drug-related, HIV infection, and connective tissue/autoimmune disorders (such as scleroderma).
- a type of PAH is associated pulmonary arterial hypertension (APAH).
- APAH can be PAH associated with other medical conditions including, for example, (1) collagen vascular disease (or connective tissue disease) which include autoimmune diseases such as scleroderma or lupus; (2) congenital heart and lung disease; (3) portal hypertension (e.g., resulting from liver disease); (4) HIV infection; (5) drugs (e.g., appetite suppressants, cocaine, and amphetamines; and (6) other conditions including thyroid disorders, glycogen storage disease, Gaucher disease, hereditary hemorrhagic telangiectasia, hemoglobinopathies, myeloproliferative disorders, and splenectomy.
- APAH can also be PAH associated with abnormal narrowing in the pulmonary veins and/or capillaries such as in pulmonary veno-occlusive disease (PVOD) and pulmonary capillary hemangiomatosis.
- PVOD pulmonary veno-occlusive disease
- Serotonin (5-hydroxytryptamine, 5-HT) is a neurotransmitter that modulates central and peripheral functions by acting on neurons, smooth muscle, and other cell types. 5-HT is involved in the control and modulation of multiple physiological and psychological processes, including in lung and pulmonary diseases.
- the literature discloses the relationship between 5-HT and pulmonary diseases at PloS One 7, e31617 (2012), “The Role of Circulating Serotonin in the Development of Chronic Obstructive Pulmonary Disease” and Thorax 1999, 54, 161-168, “Role of Serotonin in the Pathogenesis of Acute and Chronic Pulmonary Hypertension”.
- the rate-limiting step in 5-HT biosynthesis is the hydroxylation of tryptophan by dioxygen, which is catalyzed by tryptophan hydroxylase (TPH; EC 1.14.16.4) in the presence of the cofactor (6R)-L-erythro-5,6,7,8-tetrahydrobiopterin (BH4).
- TPH tryptophan hydroxylase
- 6R cofactor 6-R
- 5-hydroxy tryptophan 5-HTT
- AAAD aromatic amino acid decarboxylase
- TPH belongs to the pterin-dependent aromatic amino acid hydroxylase family.
- TPH1 and TPH2 Two vertebrate isoforms of TPH, namely TPH1 and TPH2, have been identified.
- TPH1 is primarily expressed in the pineal gland and non-neuronal tissues, such as entei chromaffin (EC) cells located in the gastrointestinal (GI) tract.
- TPH2 (the dominant form in the brain) is expressed exclusively in neuronal cells, such as dorsal raphe or myenteric plexus cells.
- the peripheral and central systems involved in 5-HT biosynthesis are isolated, with 5-HT being unable to cross the blood-brain barrier. Therefore, the pharmacological effects of 5-HT can be modulated by agents affecting TPH in the periphery, mainly TPH1 in the gut.
- WO 2015/035113 and U.S. Pat. No. 9,199,994 disclose spirocyclic compounds that act as inhibitors of THP and are useful in the treatment of various diseases and disorders associated with peripheral serotonin, including cardiovascular diseases of pulmonary arterial hypertension (PAH) and associated pulmonary arterial hypertension (APAH).
- PAH pulmonary arterial hypertension
- APAH pulmonary arterial hypertension
- a method of treating or preventing PAH/APAH in a patient has the step of administering to the patient a therapeutically effective amount of a compound selected from the group consisting of (i) (S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate, (ii) (S)-8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroeth-oxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylic acid, and (iii) a combination of the foregoing.
- the therapeutically selected from the group consisting of (i
- a method of treating or preventing PAH/APAH in a patient has the step of administering to the patient a therapeutically effective amount of a composition including a compound selected from the group consisting of (i) (S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate, (ii) (S)-8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroeth-oxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylic acid, and (iii) a combination of the foregoing
- a method of treating or preventing PAH/APAH in a patient has the step of administering to the patient a composition including a therapeutically effective amount of a compound selected from the group consisting of (i) (S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate or a pharmaceutically acceptable salt thereof, (ii) (S)-8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroeth-oxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylic acid or a pharmaceutically acceptable salt
- a therapeutically effective amount of a compound in treating PAH/APAH is selected from the group consisting of (i) (S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate or a pharmaceutically acceptable salt thereof and (ii) (S)-8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroeth-oxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylic acid or a pharmaceutically acceptable salt thereof, and (iii) a combination of the foregoing.
- a method of treating or preventing PAH/APAH in a patient has the step of administering to the patient a therapeutically effective amount of a compound selected from the group consisting of (i) (S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate or a pharmaceutically acceptable salt thereof, (ii) (S)-8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroeth-oxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylic acid or a pharmaceutically acceptable salt thereof, and (
- a method of treating or preventing PAH/APAH in a patient has the step of administering to the patient a therapeutically effective amount of a THP1 inhibitor from about 1 mg/kg/day to about 50 mg/kg/day.
- a method of treating or preventing pulmonary arterial hypertension or associated pulmonary arterial hypertension in a patient has the step of administering to the patient a therapeutically effective amount of a compound selected from the group consisting of (i) (S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate or a pharmaceutically acceptable salt thereof, (ii) (S)-8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroeth-oxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylic acid or a pharmaceutical
- FIG. 1 is a plot of an XRPD of a crystalline compound of (S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate according to the present disclosure (crystalline Form 3).
- FIG. 2 is a plot of an XRPD of a crystalline compound of (S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate of a different polymorphic form than that of FIG. 1 (crystalline Form 1).
- Pulmonary arterial hypertension (PAH) and associated pulmonary arterial hypertension (APAH) is treated via administration of either or both of two spirocyclic compounds.
- PAH Pulmonary arterial hypertension
- APAH pulmonary arterial hypertension
- each of the two spirocyclic compounds act to inhibit the formation of 5-HT, and, thus, diminish or ameliorate effects of PAH/APAH.
- a useful spirocyclic compound is (S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate (also referred to herein as “RVT-1201”).
- the compound has the following formula:
- the above-referenced compound can be used to prevent or treat PAH/APAH in either an amorphous or crystalline form.
- Two different polymorph crystalline forms are identified by x-ray powder diffraction patterns set forth in FIG. 1 (Form 3) and FIG. 2 (Form 1) as well as Tables 1 and 2 (Form 3) and Tables 3 and 4 (Form 1).
- the crystalline Form 3 polymorph might be preferred, as it exhibits substantially greater stability and shelf life compared to the crystalline Form 1 polymorph, particularly at temperatures of less than 95° C.
- the Form 3 crystalline polymorph exhibits a characteristic XRPD peak at 19.05 ⁇ 0.20 (° 2 ⁇ ).
- the Form 1 crystalline compound exhibits the XRPD (X-ray powder diffraction) pattern set forth below in Table 3.
- Form 1 crystalline compound exhibits prominent XRPD peaks set forth below in Table 4.
- the amorphous form of the RVT-1201 compound can be prepared by the method set forth in Example 63i of U.S. Pat. No. 9,199,994 (corresponding to WO2015/054202), which is incorporated by reference herein in its entirety.
- the amorphous form can then be converted to crystalline form by extraction with organic solvents, such as C4 to C10 alcohols, C4 to C10 alkyl acetates, and ethers.
- organic solvents such as C4 to C10 alcohols, C4 to C10 alkyl acetates, and ethers.
- Useful alcohols include pentane, hexane, and heptane.
- a useful ether is methyl tert butyl ether (MTBE).
- crystalline form 1 can be prepared by extraction with isopropanol, ethanol, cyclohexane, ethyl acetate, acetone, water, and mixtures of the foregoing, while crystalline Form 3 can be prepared by extraction with MTBE and/or heptane.
- Crystalline Forms 1 and 3 can be prepared by the extraction techniques set forth in U.S. Provisional Application No. 62/767,171, filed Nov. 14, 2018, which is incorporated by reference herein in its entirety.
- Another useful spirocyclic compound is (S)-8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroeth-oxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]deca ne-3-carboxylic acid (herein alternately referred to as “KAR5417”) of the following formula:
- the amorphous form of the KAR5417 compound can be prepared by the method set forth in Example 34c of U.S. Pat. No. 9,199,994.
- phrases “pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
- the term “patient” refers to any animal, including mammals, preferably mice, rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep, horses, or primates, and, most preferably, humans. Humans are inclusive of humans of any age, including adults and children, including infants.
- the phrase “therapeutically effective amount” refers to the amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue, system, animal, individual or human that is being sought by a researcher, veterinarian, medical doctor or other clinician.
- treating refers to 1) inhibiting the disease; for example, inhibiting a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e., arresting further development of the pathology and/or symptomatology), or 2) ameliorating the disease; for example, ameliorating a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e., reversing the pathology and/or symptomatology).
- the term “preventing” or “prevention” refers to reducing risk incidence, delaying, or inhibiting the onset or worsening of the disease; for example, in an individual who may be predisposed to the disease, condition or disorder but does not yet experience or display the pathology or symptomatology of the disease, or an individual who has previously suffered from the disease, condition or disorder, but has been treated and, e.g., no longer displays the pathology or symptomatology of the disease.
- the spirocyclic compounds can be administered to patients (animals or humans) in need of such treatment in appropriate dosages that will provide prophylactic and/or therapeutic efficacy.
- the dose required for use in the treatment or prevention of any particular disease or disorder will typically vary from patient to patient depending on, for example, particular compound or composition selected, the route of administration, the nature of the condition being treated, the age and condition of the patient, concurrent medication or special diets then being followed by the patient, and other factors.
- the appropriate dosage can be determined by the treating physician; however, the dosage will be within the parameters defined herein.
- the spirocyclic compounds can be administered systemically orally, subcutaneously, parenterally, by inhalation spray or rectally in dosage unit formulations containing pharmaceutically acceptable carriers, adjuvants and vehicles.
- Parenteral administration can involve subcutaneous injections, intravenous or intramuscular injections or infusion techniques.
- Injectable liquids can include aqueous and/or organic components.
- Treatment duration can be as long as deemed necessary by a treating physician.
- the compositions can be administered as often as needed, e.g., one to four (or more) or more times per day. Administration can take place twice daily, thrice daily, daily, weekly, biweekly, twice weekly, every other week, monthly, and the like.
- a treatment period can terminate when a desired result, for example, a particular therapeutic effect, is achieved. However, in some instances, a treatment period can be continued indefinitely.
- compositions can be prepared as solid dosage forms for oral administration (e.g., capsules, tablets, pills, dragees, powders, granules and the like). Tablets can be prepared by compression and/or molding. Compressed tablets can include pharmaceutically acceptable excipients, such as, but not limited to, binders, lubricants, glidants, inert diluents, preservatives, disintegrants, and dispersing agents. Tablets and other solid dosage forms, such as, but not limited to, capsules, pills, powders, and granules, can include coatings, such as enteric coatings.
- Liquid dosage forms for oral administration can include, for example, vehicles such as, but not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.
- the liquid vehicles can have aqueous and/or organic components.
- Suspensions can include one or more suspending agents.
- ingredients useful in liquid dosage forms include, but are not limited to, chelants, sequestering agents, viscosifiers, thickeners, penetration enhancers, solvents, emulsifiers, and emollients.
- compositions suitable for parenteral administration can include the spirocyclic compound together with one or more pharmaceutically acceptable sterile isotonic aqueous or non-aqueous solutions, dispersions, suspensions or emulsions.
- the composition can be in the form of a sterile powder that can be reconstituted into a sterile injectable solutions or dispersion just prior to use.
- Solid and liquid dosage forms can be formulated such that they conform to a desired release profile, e.g., immediate release, delayed release, and extended or sustained release.
- the amount of spirocyclic compound to be administered will vary depending on factors such as the following: the spirocyclic compound selected, method of administration, release profile, and composition formulation.
- a typical dosage will be about 1 mg/kg/day to about 50 mg/kg/day and more typically from about 5 mg/kg/day to about 30 mg/kg/day, based on the weight of the patient.
- a most preferred spirocyclic compound is RVT-1201 in crystalline Form 3.
- Individual oral dosage forms typically have from about 50 mg to about 3000 mg of a spirocyclic compound and additional amounts of one or more pharmaceutically acceptable excipients.
- Other useful individual oral dosage forms can, by way of example, have spirocyclic compound in amounts of 100 mg, 150 mg, 200 mg, 250 mg, 300 mg, 350 mg, or 400 mg, 450 mg, 500 mg, 550 mg, 575 mg, 600 mg, 625 mg, 650 mg, 675 mg, 700 mg, 725 mg, 750 mg, 775 mg, 800 mg, 900 mg, 950 mg, 1000 mg, 1050 mg, 1100 mg, 1150 mg, and about 1200 mg, particularly 1200 mg.
- a preferred dosage is 1200 mg.
- wt % means weight percent based on the total weight of the composition or formulation.
- compositions e.g., pharmaceutical compositions, useful for the treatment of PAH and/or APAH, and methods to treat PAH and/or APAH with such compositions.
- the compositions have one or more TPH1 inhibitors disclosed herein, and one or more pharmaceutically acceptable excipients.
- compositions of the present disclosure can comprise from about 10 mg to about 3000 mg of the one or more spirocyclic compounds disclosed herein, and one or more pharmaceutically acceptable excipients.
- the compositions of the present disclosure can comprise 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, 110 mg, 120 mg, 130 mg, 140 mg, 150 mg, 160 mg, 170 mg, 180 mg, 190 mg, 200 mg, 210 mg, 220 mg, 230 mg, 240 mg, 250 mg, 260 mg, 270 mg, 280 mg, 290 mg, 300 mg, 310 mg, 320 mg, 330 mg, 340 mg, 350 mg, 360 mg, 370 mg, 380 mg, 390 mg, 400 mg, 410 mg, 420 mg, 430 mg, 440 mg, 450 mg, 460 mg, 470 mg, 480 mg, 490 mg, 500 mg, 510 mg, 520 mg, 530 mg, 540 mg, 550 mg, 560
- compositions may have from about 10 mg to about 1400 mg of one or more TPH1 indicators disclosed herein, and one or more pharmaceutically acceptable excipients.
- THP1 inhibitors include phenylalanine-derived TPH1 inhibitors, such as p-chlorophenylalanine and p-Ethynyl phenylalanine. See “p-Ethynylphenylalanine: A Potent Inhibitor Of Tryptophan Hydroxylase”, Journal of Neurochemistry 74, 2067-73 (2000).
- Other useful THP1 inhibitors include substituted 3-(4-(1,3,5-triazin-2-yl)-phenyl)-2-aminopropanoic acids.
- PAH and APAH are forms of PH, with APAH also being a form of PAH.
- Other forms of PAH include idiopathic pulmonary arterial hypertension (IPAH) and heritable pulmonary arterial hypertension (HPAH).
- IPAH is a form of PAH that arises without any apparent origin or cause.
- HPAH is a form of PAH that arises due to mutations in PAH predisposing genes or from hereditary origin
- RVT-1201 In rat, orally administered RVT-1201 at a dose of 100 mg/kg/day (KAR5417 AUC 0-24 ng ⁇ h/mL) may block or ameliorate PAH in both a monocrotaline prevention model and a SUGEN-hypoxia treatment model for established PAH.
- RVT-1201 (30 to 300 mg/kg/day) may yield a dose-dependent reduction in rat serum serotonin ( ⁇ 27% to ⁇ 96%) and 24 h urinary output of 5-HIAA ( ⁇ 45% to ⁇ 56%).
- HIAA is a metabolite that reflects total serotonin biosynthesis.
- TPH1 is the rate-limiting enzyme for peripheral biosynthesis of serotonin (5HT), which has been implicated as a causative factor in PAH.
- RVT-1201 decreased pulmonary vessel wall thickness in 2 PAH rodent models indicating potential to halt/reverse pulmonary remodeling in humans.
- the median effective dose (100 mg/kg QD) in PAH rat models yielded a ⁇ 35% reduction in 5-HT biosynthesis (based on urinary 5-HIAA, a metabolite of 5HT).
- 5-HT lowering was similar across both dose regimens, with 800 mg QD achieving mean ( ⁇ SD) 40.0 (6.32) % and (6.59) % reductions in plasma and urinary 5-HIAA at day 14, respectively, compared to 49.9 (9.52) % and 55.5 (10.3) % reductions, respectively, with the 400 mg BID regimen. Plasma and urinary 5-HIAA levels were largely unchanged from BSL in the PBO arms.
- RVT-1201 Once daily oral dosing of RVT-1201 achieved reductions in serotonin biosynthesis comparable to those associated with reversal of vascular remodeling in PAH animal models. Repeated QD dosing of RVT-1201 reduced 5-HT biosynthesis similarly to divided (BID) daily dosing. Reductions in 5-HIAA levels were comparable to those associated with reversal of vascular remodeling in animal PAH models. RVT-1201 was generally well-tolerated in both dose regimens.
- RVT-1201 has the potential to reduce serotonin production and impact vascular remodeling in PAH patients. If ultimately proven effective, the potential to dose RVT-1201 once-daily may help improve overall treatment adherence in a disease like PAH in which patients often take more than one drug in combination chronically.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
There is a method of treating or preventing pulmonary arterial hypertension (PAH) or associated pulmonary arterial hypertension (APAH) in a patient. The method has the step of systemically administering to the patient a therapeutically effective amount of one or more compounds: (S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate or a pharmaceutically acceptable salt thereof, or (S)-8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroeth-oxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylic acid or a pharmaceutically acceptable salt thereof, or a combination of the foregoing. There is also a method of treating or preventing PAH or APAH in a patient by systemically administering a therapeutically effective amount of a THP1 inhibitor from about 1 mg/kg/day to about 50 mg/kg/day. There is a method for treating PAH or APAH in a patient with a single daily dose.
Description
- The present application claims priority based on U.S. Provisional Application No. 62/819,162, filed Mar. 15, 2019, which is incorporated herein by reference in its entirety.
- The present disclosure relates to a method for treating pulmonary arterial hypertension (PAH) and associated pulmonary arterial hypertension (APAH) in a patient. The present disclosure further relates to a method for treating PAH/APAH via a systemic administration to a patient. The present disclosure yet further relates to a method for treating PAH/APAH in a patient with a single daily dose.
- Pulmonary arterial hypertension (PAH) is one form of a broader condition known as pulmonary hypertension, which means high blood pressure in the lungs. In PAH, increased pressure in the vessels is caused by obstruction in small arteries in the lungs and/or constriction or narrowing in diameter, which increases the resistance to blood flow through the lungs. Over time, the increased blood pressure can damage the heart. In many cases of pulmonary arterial hypertension, the cause is unknown. Others causes can be drug-related, HIV infection, and connective tissue/autoimmune disorders (such as scleroderma).
- A type of PAH is associated pulmonary arterial hypertension (APAH). APAH can be PAH associated with other medical conditions including, for example, (1) collagen vascular disease (or connective tissue disease) which include autoimmune diseases such as scleroderma or lupus; (2) congenital heart and lung disease; (3) portal hypertension (e.g., resulting from liver disease); (4) HIV infection; (5) drugs (e.g., appetite suppressants, cocaine, and amphetamines; and (6) other conditions including thyroid disorders, glycogen storage disease, Gaucher disease, hereditary hemorrhagic telangiectasia, hemoglobinopathies, myeloproliferative disorders, and splenectomy. APAH can also be PAH associated with abnormal narrowing in the pulmonary veins and/or capillaries such as in pulmonary veno-occlusive disease (PVOD) and pulmonary capillary hemangiomatosis.
- Serotonin (5-hydroxytryptamine, 5-HT) is a neurotransmitter that modulates central and peripheral functions by acting on neurons, smooth muscle, and other cell types. 5-HT is involved in the control and modulation of multiple physiological and psychological processes, including in lung and pulmonary diseases. The literature discloses the relationship between 5-HT and pulmonary diseases at PloS One 7, e31617 (2012), “The Role of Circulating Serotonin in the Development of Chronic Obstructive Pulmonary Disease” and Thorax 1999, 54, 161-168, “Role of Serotonin in the Pathogenesis of Acute and Chronic Pulmonary Hypertension”.
- The rate-limiting step in 5-HT biosynthesis is the hydroxylation of tryptophan by dioxygen, which is catalyzed by tryptophan hydroxylase (TPH; EC 1.14.16.4) in the presence of the cofactor (6R)-L-erythro-5,6,7,8-tetrahydrobiopterin (BH4). The resulting oxidized product, 5-hydroxy tryptophan (5-HTT) is subsequently decarboxylated by an aromatic amino acid decarboxylase (AAAD; EC 4.1.1.28) to produce 5-HT. Together with phenylalanine hydroxylase (PheOH) and tyrosine hydroxylase (TH), TPH belongs to the pterin-dependent aromatic amino acid hydroxylase family.
- Two vertebrate isoforms of TPH, namely TPH1 and TPH2, have been identified. TPH1 is primarily expressed in the pineal gland and non-neuronal tissues, such as entei chromaffin (EC) cells located in the gastrointestinal (GI) tract. TPH2 (the dominant form in the brain) is expressed exclusively in neuronal cells, such as dorsal raphe or myenteric plexus cells. The peripheral and central systems involved in 5-HT biosynthesis are isolated, with 5-HT being unable to cross the blood-brain barrier. Therefore, the pharmacological effects of 5-HT can be modulated by agents affecting TPH in the periphery, mainly TPH1 in the gut.
- WO 2015/035113 and U.S. Pat. No. 9,199,994 disclose spirocyclic compounds that act as inhibitors of THP and are useful in the treatment of various diseases and disorders associated with peripheral serotonin, including cardiovascular diseases of pulmonary arterial hypertension (PAH) and associated pulmonary arterial hypertension (APAH).
- However, there is a need for a method of treating or preventing PAH/APAH in a patient. There is a further need for a method of treating or preventing PAH/APAH in a patient with a systemic administration of a pharmaceutical compound or composition effective in modulating or ameliorating the effects of PAH/APAH. There is yet further need for a method of treating or preventing PAH/APAH in a patient with a pharmaceutical compound or composition containing a THP1 inhibitor.
- According to the present disclosure, there is provided a method of treating or preventing PAH/APAH in a patient. The method has the step of administering to the patient a therapeutically effective amount of a compound selected from the group consisting of (i) (S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate, (ii) (S)-8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroeth-oxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylic acid, and (iii) a combination of the foregoing. The therapeutically effective amount of the compound ranges from about 10 mg/kg/day to about 1000 mg/kg/day.
- According to the present disclosure, there is provided a method of treating or preventing PAH/APAH in a patient. The method has the step of administering to the patient a therapeutically effective amount of a composition including a compound selected from the group consisting of (i) (S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate, (ii) (S)-8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroeth-oxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylic acid, and (iii) a combination of the foregoing, together with one or more pharmaceutically acceptable excipients. The therapeutically effective amount of the compound ranges from about 10 mg/kg/day to about 1000 mg/kg/day.
- According to the present disclosure, there is provided a method of treating or preventing PAH/APAH in a patient. The method has the step of administering to the patient a composition including a therapeutically effective amount of a compound selected from the group consisting of (i) (S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate or a pharmaceutically acceptable salt thereof, (ii) (S)-8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroeth-oxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylic acid or a pharmaceutically acceptable salt thereof, and (iii) a combination of the foregoing and a pharmaceutically acceptable excipient. The therapeutically effective amount of the compound ranges from about 10 mg/kg/day to about 1000 mg/kg/day.
- According to the present disclosure, there is provided the use of a therapeutically effective amount of a compound in treating PAH/APAH. The compound is selected from the group consisting of (i) (S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate or a pharmaceutically acceptable salt thereof and (ii) (S)-8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroeth-oxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylic acid or a pharmaceutically acceptable salt thereof, and (iii) a combination of the foregoing. The therapeutically effective amount of the compound ranges from about 10 mg/kg/day to about 1000 mg/kg/day.
- According to the present disclosure, there is provided a method of treating or preventing PAH/APAH in a patient. The method has the step of administering to the patient a therapeutically effective amount of a compound selected from the group consisting of (i) (S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate or a pharmaceutically acceptable salt thereof, (ii) (S)-8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroeth-oxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylic acid or a pharmaceutically acceptable salt thereof, and (iii) a combination of the foregoing.
- According to the present disclosure, there is provided a method of treating or preventing PAH/APAH in a patient. The method has the step of administering to the patient a therapeutically effective amount of a THP1 inhibitor from about 1 mg/kg/day to about 50 mg/kg/day.
- According to the present disclosure, there is provided a method of treating or preventing pulmonary arterial hypertension or associated pulmonary arterial hypertension in a patient. The method has the step of administering to the patient a therapeutically effective amount of a compound selected from the group consisting of (i) (S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate or a pharmaceutically acceptable salt thereof, (ii) (S)-8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroeth-oxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylic acid or a pharmaceutically acceptable salt thereof, and (iii) a combination of the foregoing. The compound or pharmaceutically acceptable salt thereof is administered once per day.
- Embodiments of the present disclosure are described herein with reference to the following figures.
-
FIG. 1 is a plot of an XRPD of a crystalline compound of (S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate according to the present disclosure (crystalline Form 3). -
FIG. 2 is a plot of an XRPD of a crystalline compound of (S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate of a different polymorphic form than that ofFIG. 1 (crystalline Form 1). - Pulmonary arterial hypertension (PAH) and associated pulmonary arterial hypertension (APAH) is treated via administration of either or both of two spirocyclic compounds. Without being bound to any theory, each of the two spirocyclic compounds act to inhibit the formation of 5-HT, and, thus, diminish or ameliorate effects of PAH/APAH.
- A useful spirocyclic compound is (S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate (also referred to herein as “RVT-1201”). The compound has the following formula:
- The above-referenced compound can be used to prevent or treat PAH/APAH in either an amorphous or crystalline form. Two different polymorph crystalline forms are identified by x-ray powder diffraction patterns set forth in
FIG. 1 (Form 3) andFIG. 2 (Form 1) as well as Tables 1 and 2 (Form 3) and Tables 3 and 4 (Form 1). The crystalline Form 3 polymorph might be preferred, as it exhibits substantially greater stability and shelf life compared to the crystalline Form 1 polymorph, particularly at temperatures of less than 95° C. -
TABLE 1 Observed Peaks for X-ray Powder Diffraction Pattern for Compound RVT-1201, Crystalline Form 3 Peak position (°2θ) d space (Å) Intensity (%) 8.78 ± 0.20 10.077 ± 0.235 90 12.00 ± 0.20 7.375 ± 0.125 25 13.47 ± 0.20 6.573 ± 0.099 39 14.02 ± 0.20 6.316 ± 0.091 12 14.87 ± 0.20 5.956 ± 0.081 71 15.39 ± 0.20 5.757 ± 0.075 72 15.61 ± 0.20 5.677 ± 0.073 78 15.89 ± 0.20 5.576 ± 0.071 50 16.31 ± 0.20 5.434 ± 0.067 7 17.70 ± 0.20 5.011 ± 0.057 34 18.45 ± 0.20 4.809 ± 0.052 70 19.05 ± 0.20 4.658 ± 0.049 100 20.12 ± 0.20 4.413 ± 0.044 42 20.57 ± 0.20 4.317 ± 0.042 68 20.84 ± 0.20 4.262 ± 0.041 39 21.46 ± 0.20 4.141 ± 0.039 49 21.94 ± 0.20 4.051 ± 0.037 18 22.56 ± 0.20 3.941 ± 0.035 31 22.90 ± 0.20 3.884 ± 0.034 17 23.90 ± 0.20 3.723 ± 0.031 35 24.32 ± 0.20 3.660 ± 0.030 13 25.07 ± 0.20 3.552 ± 0.028 12 26.54 ± 0.20 3.359 ± 0.025 17 26.76 ± 0.20 3.332 ± 0.025 18 27.79 ± 0.20 3.210 ± 0.023 8 28.21 ± 0.20 3.163 ± 0.022 19 29.48 ± 0.20 3.030 ± 0.020 9 -
TABLE 2 Prominent Observed Peaks for X-ray Powder Diffraction Pattern for Compound RVT-1201, Crystalline Form 3 Peak position (°2θ) d space (Å) Intensity (%) 8.78 ± 0.20 10.077 ± 0.235 90 14.87 ± 0.20 5.956 ± 0.081 71 15.39 ± 0.20 5.757 ± 0.075 72 15.61 ± 0.20 5.677 ± 0.073 78 18.45 ± 0.20 4.809 ± 0.052 70 19.05 ± 0.20 4.658 ± 0.049 100 - In yet another aspect, the Form 3 crystalline polymorph exhibits a characteristic XRPD peak at 19.05±0.20 (° 2θ).
- The Form 1 crystalline compound exhibits the XRPD (X-ray powder diffraction) pattern set forth below in Table 3.
-
TABLE 3 Observed Peaks for X-Ray Powder Diffraction Pattern for Compound RVT-1201, Crystalline Form 1 d space Intensity Peak position (°2θ) (Å) (%) 5.92 ± 0.20 14.936 ± 0.522 27 9.01 ± 0.20 9.816 ± 0.222 11 9.68 ± 0.20 9.140 ± 0.192 9 10.38 ± 0.20 8.523 ± 0.167 9 10.95 ± 0.20 8.082 ± 0.150 30 11.85 ± 0.20 7.468 ± 0.128 6 12.90 ± 0.20 6.861 ± 0.108 43 13.89 ± 0.20 6.376 ± 0.093 65 14.62 ± 0.20 6.057 ± 0.084 31 15.04 ± 0.20 5.890 ± 0.079 44 15.41 ± 0.20 5.750 ± 0.075 38 17.13 ± 0.20 5.176 ± 0.061 30 17.83 ± 0.20 4.974 ± 0.056 37 18.72 ± 0.20 4.741 ± 0.051 14 19.44 ± 0.20 4.567 ± 0.047 100 19.79 ± 0.20 4.487 ± 0.045 30 20.11 ± 0.20 4.417 ± 0.044 97 20.34 ± 0.20 4.366 ± 0.043 44 20.84 ± 0.20 4.262 ± 0.041 14 21.41 ± 0.20 4.151 ± 0.039 10 21.88 ± 0.20 4.063 ± 0.037 11 22.28 ± 0.20 3.991 ± 0.036 25 22.83 ± 0.20 3.895 ± 0.034 60 23.85 ± 0.20 3.731 ± 0.031 13 24.40 ± 0.20 3.648 ± 0.030 9 25.45 ± 0.20 3.500 ± 0.027 9 25.97 ± 0.20 3.431 ± 0.026 12 27.22 ± 0.20 3.276 ± 0.024 15 27.58 ± 0.20 3.235 ± 0.023 23 28.06 ± 0.20 3.180 ± 0.022 12 28.66 ± 0.20 3.115 ± 0.021 7 - In still another aspect, the Form 1 crystalline compound exhibits prominent XRPD peaks set forth below in Table 4.
-
TABLE 4 Prominent Observed Peaks for X-Ray Powder Diffraction Pattern for Compound RVT-1201, Crystalline Form 1 Peak position (°2θ) d space (Å) Intensity (%) 12.90 ± 0.20 6.861 ± 0.108 43 13.89 ± 0.20 6.376 ± 0.093 65 15.04 ± 0.20 5.890 ± 0.079 44 19.44 ± 0.20 4.567 ± 0.047 100 20.11 ± 0.20 4.417 ± 0.044 97 20.34 ± 0.20 4.366 ± 0.043 44 22.83 ± 0.20 3.895 ± 0.034 60 - The amorphous form of the RVT-1201 compound can be prepared by the method set forth in Example 63i of U.S. Pat. No. 9,199,994 (corresponding to WO2015/054202), which is incorporated by reference herein in its entirety. The amorphous form can then be converted to crystalline form by extraction with organic solvents, such as C4 to C10 alcohols, C4 to C10 alkyl acetates, and ethers. Useful alcohols include pentane, hexane, and heptane. A useful ether is methyl tert butyl ether (MTBE). By way of example, crystalline form 1 can be prepared by extraction with isopropanol, ethanol, cyclohexane, ethyl acetate, acetone, water, and mixtures of the foregoing, while crystalline Form 3 can be prepared by extraction with MTBE and/or heptane. Crystalline Forms 1 and 3 can be prepared by the extraction techniques set forth in U.S. Provisional Application No. 62/767,171, filed Nov. 14, 2018, which is incorporated by reference herein in its entirety.
- Another useful spirocyclic compound is (S)-8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroeth-oxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]deca ne-3-carboxylic acid (herein alternately referred to as “KAR5417”) of the following formula:
- The amorphous form of the KAR5417 compound can be prepared by the method set forth in Example 34c of U.S. Pat. No. 9,199,994.
- The phrase “pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
- The efficacy of amorphous (S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate in inhibiting TPH1 in mice was demonstrated in U.S. Pat. No. 9,199,994 in biological assays at Example 63i and Table 27.
- As used herein, the term “patient” is used interchangeably, refers to any animal, including mammals, preferably mice, rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep, horses, or primates, and, most preferably, humans. Humans are inclusive of humans of any age, including adults and children, including infants.
- As used herein, the phrase “therapeutically effective amount” refers to the amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue, system, animal, individual or human that is being sought by a researcher, veterinarian, medical doctor or other clinician.
- As used herein, the term “treating” or “treatment” refers to 1) inhibiting the disease; for example, inhibiting a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e., arresting further development of the pathology and/or symptomatology), or 2) ameliorating the disease; for example, ameliorating a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e., reversing the pathology and/or symptomatology).
- As used herein, the term “preventing” or “prevention” refers to reducing risk incidence, delaying, or inhibiting the onset or worsening of the disease; for example, in an individual who may be predisposed to the disease, condition or disorder but does not yet experience or display the pathology or symptomatology of the disease, or an individual who has previously suffered from the disease, condition or disorder, but has been treated and, e.g., no longer displays the pathology or symptomatology of the disease.
- The spirocyclic compounds can be administered to patients (animals or humans) in need of such treatment in appropriate dosages that will provide prophylactic and/or therapeutic efficacy. The dose required for use in the treatment or prevention of any particular disease or disorder will typically vary from patient to patient depending on, for example, particular compound or composition selected, the route of administration, the nature of the condition being treated, the age and condition of the patient, concurrent medication or special diets then being followed by the patient, and other factors. The appropriate dosage can be determined by the treating physician; however, the dosage will be within the parameters defined herein.
- The spirocyclic compounds can be administered systemically orally, subcutaneously, parenterally, by inhalation spray or rectally in dosage unit formulations containing pharmaceutically acceptable carriers, adjuvants and vehicles. Parenteral administration can involve subcutaneous injections, intravenous or intramuscular injections or infusion techniques. Injectable liquids can include aqueous and/or organic components. Treatment duration can be as long as deemed necessary by a treating physician. The compositions can be administered as often as needed, e.g., one to four (or more) or more times per day. Administration can take place twice daily, thrice daily, daily, weekly, biweekly, twice weekly, every other week, monthly, and the like. A treatment period can terminate when a desired result, for example, a particular therapeutic effect, is achieved. However, in some instances, a treatment period can be continued indefinitely.
- In some embodiments, pharmaceutical compositions can be prepared as solid dosage forms for oral administration (e.g., capsules, tablets, pills, dragees, powders, granules and the like). Tablets can be prepared by compression and/or molding. Compressed tablets can include pharmaceutically acceptable excipients, such as, but not limited to, binders, lubricants, glidants, inert diluents, preservatives, disintegrants, and dispersing agents. Tablets and other solid dosage forms, such as, but not limited to, capsules, pills, powders, and granules, can include coatings, such as enteric coatings.
- Liquid dosage forms for oral administration can include, for example, vehicles such as, but not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. The liquid vehicles can have aqueous and/or organic components. Suspensions can include one or more suspending agents. Examples of ingredients useful in liquid dosage forms include, but are not limited to, chelants, sequestering agents, viscosifiers, thickeners, penetration enhancers, solvents, emulsifiers, and emollients.
- Pharmaceutical compositions suitable for parenteral administration can include the spirocyclic compound together with one or more pharmaceutically acceptable sterile isotonic aqueous or non-aqueous solutions, dispersions, suspensions or emulsions.
- Alternatively, the composition can be in the form of a sterile powder that can be reconstituted into a sterile injectable solutions or dispersion just prior to use.
- Solid and liquid dosage forms can be formulated such that they conform to a desired release profile, e.g., immediate release, delayed release, and extended or sustained release.
- The amount of spirocyclic compound to be administered will vary depending on factors such as the following: the spirocyclic compound selected, method of administration, release profile, and composition formulation. Typically, for the two spirocyclic compounds, in an oral dosage form to treat or prevent PAH/APAH, a typical dosage will be about 1 mg/kg/day to about 50 mg/kg/day and more typically from about 5 mg/kg/day to about 30 mg/kg/day, based on the weight of the patient. A most preferred spirocyclic compound is RVT-1201 in crystalline Form 3. Individual oral dosage forms typically have from about 50 mg to about 3000 mg of a spirocyclic compound and additional amounts of one or more pharmaceutically acceptable excipients. Other useful individual oral dosage forms can, by way of example, have spirocyclic compound in amounts of 100 mg, 150 mg, 200 mg, 250 mg, 300 mg, 350 mg, or 400 mg, 450 mg, 500 mg, 550 mg, 575 mg, 600 mg, 625 mg, 650 mg, 675 mg, 700 mg, 725 mg, 750 mg, 775 mg, 800 mg, 900 mg, 950 mg, 1000 mg, 1050 mg, 1100 mg, 1150 mg, and about 1200 mg, particularly 1200 mg. A preferred dosage is 1200 mg. Other amounts between 50 mg to 3000 mg are possible, for example, from about 325 mg to about 475 mg, from about 350 mg to about 500 mg, from about 375 to about 525 mg, from about 400 mg to about 550 mg, from about 425 mg to about 575 mg, from about 450 mg to about 600 mg, from about 475 mg to about 625 mg, from about 500 mg to about 650 mg, from about 525 mg to about 675 mg, from about 550 mg to about 700 mg, from about 575 mg to about 725 mg, from about 600 mg to about 750 mg, from about 625 mg to about 775 mg, from about 650 mg to about 800 mg, from about 675 mg to about 825 mg, from about 700 mg to about 850 mg, from about 725 mg to about 875 mg, from about 750 mg to about 900 mg, from about 775 mg to about 925 mg, from about 800 mg to about 950 mg, from about 825 to about 975, from about 850 mg to about 1000 mg, from about 900 mg to about 1150 mg, from about 1000 mg to about 1150 mg, from about 1100 mg to about 1250 mg, and from about 1200 mg to about 1350 mg.
- “wt %” means weight percent based on the total weight of the composition or formulation.
- According to the present disclosure, there is also provided a method of treating or preventing PAH/APAH in a patient by administering to the patient a therapeutically effective amount of a THP1 inhibitor in the methods of administration and dosing levels described above. Further according to the present disclosure, there are also provided compositions, e.g., pharmaceutical compositions, useful for the treatment of PAH and/or APAH, and methods to treat PAH and/or APAH with such compositions. The compositions have one or more TPH1 inhibitors disclosed herein, and one or more pharmaceutically acceptable excipients.
- The compositions of the present disclosure can comprise from about 10 mg to about 3000 mg of the one or more spirocyclic compounds disclosed herein, and one or more pharmaceutically acceptable excipients. The compositions of the present disclosure can comprise 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, 110 mg, 120 mg, 130 mg, 140 mg, 150 mg, 160 mg, 170 mg, 180 mg, 190 mg, 200 mg, 210 mg, 220 mg, 230 mg, 240 mg, 250 mg, 260 mg, 270 mg, 280 mg, 290 mg, 300 mg, 310 mg, 320 mg, 330 mg, 340 mg, 350 mg, 360 mg, 370 mg, 380 mg, 390 mg, 400 mg, 410 mg, 420 mg, 430 mg, 440 mg, 450 mg, 460 mg, 470 mg, 480 mg, 490 mg, 500 mg, 510 mg, 520 mg, 530 mg, 540 mg, 550 mg, 560 mg, 570 mg, 580 mg, 590 mg, 600 mg, 610 mg, 620 mg, 630 mg, 640 mg, 650 mg, 660 mg, 670 mg, 680 mg, 670 mg, 680 mg, 690 mg, 700 mg, 710 mg, 720 mg, 730 mg, 740 mg, 750 mg, 760 mg, 770 mg, 780 mg, 790 mg, 800 mg, 810 mg, 820 mg, 830 mg, 840 mg, 850 mg, 860 mg, 870 mg, 880 mg, 890 mg, 900 mg, 910 mg, 920 mg, 930 mg, 940 mg, 950 mg, 960 mg, 970 mg, 980 mg, 990 mg, 1000 mg, 1050 mg, 1100 mg, 1150 mg, 1200 mg, 1250 mg, 1300 mg, 1350 mg, and 1400 mg of the one or more spirocyclic compounds disclosed herein, and, additionally, one or more pharmaceutically acceptable excipients.
- In another embodiment of the disclosure, compositions may have from about 10 mg to about 1400 mg of one or more TPH1 indicators disclosed herein, and one or more pharmaceutically acceptable excipients.
- The spirocyclic compounds described above and pharmaceutically acceptable salts thereof are useful THP1 inhibitors. Other useful THP1 inhibitors include phenylalanine-derived TPH1 inhibitors, such as p-chlorophenylalanine and p-Ethynyl phenylalanine. See “p-Ethynylphenylalanine: A Potent Inhibitor Of Tryptophan Hydroxylase”, Journal of Neurochemistry 74, 2067-73 (2000). Other useful THP1 inhibitors include substituted 3-(4-(1,3,5-triazin-2-yl)-phenyl)-2-aminopropanoic acids. See “A Tryptophan 5-hydroxylase Inhibitor, And Its Potential In Chronic Diarrhea Associated With Increased Serotonin”, Neurogastroenterology and Motility: The Official Journal of The European Gastrointestinal Motility Society 23, 193-200 (2011); “Substituted 3-(4-(1,3,5-triazin-2-yl)-phenyl)-2-aminopropanoic Acids As Novel Tryptophan Hydroxylase Inhibitors” Bioorganic & Medicinal Chemistry Letters 19, 5229-32 (2009); “Modulation Of Peripheral Serotonin Levels By Novel Tryptophan Hydroxylase Inhibitors For The Potential Treatment Of Functional Gastrointestinal Disorders” Journal of Medicinal Chemistry 51, 3684-7 (2008); and “Discovery And Characterization of Novel Tryptophan Hydroxylase Inhibitors that Selectively Inhibit Serotonin Synthesis in the Gastrointestinal Tract”, The Journal of Pharmacology and Experimental Therapeutics, 325, 47-55 (2008)).
- The embodiments of the present disclosure are also useful in treating any form or category of pulmonary hypertension (PH) in general. PAH and APAH are forms of PH, with APAH also being a form of PAH. Other forms of PAH include idiopathic pulmonary arterial hypertension (IPAH) and heritable pulmonary arterial hypertension (HPAH). IPAH is a form of PAH that arises without any apparent origin or cause. HPAH is a form of PAH that arises due to mutations in PAH predisposing genes or from hereditary origin
- The following are examples of the disclosure and are not to be construed as limiting.
- In rat, orally administered RVT-1201 at a dose of 100 mg/kg/day (KAR5417 AUC0-24 ng·h/mL) may block or ameliorate PAH in both a monocrotaline prevention model and a SUGEN-hypoxia treatment model for established PAH. RVT-1201 (30 to 300 mg/kg/day) may yield a dose-dependent reduction in rat serum serotonin (−27% to −96%) and 24 h urinary output of 5-HIAA (−45% to −56%). HIAA is a metabolite that reflects total serotonin biosynthesis.
- Divided dose studies in rats given 75 mg/kg/day (˜65% serotonin reduction) may demonstrate KAR5417 AUC0-24, rather than Cmax or Ctrough, correlated with lowered serotonin biomarkers. Once daily administration to rats may show it is comparable to BID or TID regimens.
- Healthy human subjects (n=˜120) may receive RVT-1201. Of treatment emergent adverse events received, none will be serious, nor considered a dose limiting toxicity. With standard meals, AUC following single doses will appear proportional to dose of 200 to −1200 mg).
- At 400 mg BID (twice daily), changes in 5-HIAA will be comparable across studies. Mean change in plasma 5-HIAA may be about −53% from Day 1 to Day 14, whereas placebo may be about +26%. Interpolation of KAR5417 AUC between 400 mg and 800 mg BID regimens may show 500-600 mg BID in humans will achieve the target exposure associated with efficacy in rat models. In summary, RVT-1201 may be well tolerated in healthy subjects at doses required to achieve clinically-relevant AUC, and lowering of serotonin biomarkers for treatment of PAH.
- TPH1 is the rate-limiting enzyme for peripheral biosynthesis of serotonin (5HT), which has been implicated as a causative factor in PAH. RVT-1201 decreased pulmonary vessel wall thickness in 2 PAH rodent models indicating potential to halt/reverse pulmonary remodeling in humans. The median effective dose (100 mg/kg QD) in PAH rat models yielded a ˜35% reduction in 5-HT biosynthesis (based on urinary 5-HIAA, a metabolite of 5HT). Divided-dose pharmacodynamic (PD) studies in healthy rats (QD vs BID vs TID) demonstrated KAR5417 AUC, rather than Cmax or Cmin, best correlated with lowering of 5-HT, indicating QD dosing (once daily) was as effective as more frequent dosing. The example compares reductions in 5-HIAA levels following QD and BID dosing in healthy subjects.
- 24 healthy subjects received 800 mg total daily oral doses of RVT-1201 or placebo (PBO), either as single (800 mg QD) or divided (400 mg BID) doses for 14 days across two cohorts (9 active: 3 PBO per cohort). KAR5417 plasma levels and change from Baseline (BSL) PD biomarker data (plasma and urine 5-HIAA) were compared between QD and BID cohorts at day 14. Safety and tolerability were assessed via adverse event (AE) monitoring and laboratory, vital signs and ECG assessments.
- At day 14, KAR5417 mean (±SD) AUC0-24 at 800 mg QD (9180 ng*h/mL, ±4280) was comparable to the mean pAUC0-24 for 400 mg BID (10400 ng*h/mL, ±3260). 5-HT lowering was similar across both dose regimens, with 800 mg QD achieving mean (±SD) 40.0 (6.32) % and (6.59) % reductions in plasma and urinary 5-HIAA at day 14, respectively, compared to 49.9 (9.52) % and 55.5 (10.3) % reductions, respectively, with the 400 mg BID regimen. Plasma and urinary 5-HIAA levels were largely unchanged from BSL in the PBO arms. 5-HIAA reductions in both regimens exceeded those associated with efficacy in the rodent models. Both dose regimens were generally well-tolerated. The overall incidence of GI-related AEs was greater in the QD group (78%) compared to the divided dose group (33%). However, most AEs were mild in intensity and there were no treatment-related withdrawals in either cohort.
- Once daily oral dosing of RVT-1201 achieved reductions in serotonin biosynthesis comparable to those associated with reversal of vascular remodeling in PAH animal models. Repeated QD dosing of RVT-1201 reduced 5-HT biosynthesis similarly to divided (BID) daily dosing. Reductions in 5-HIAA levels were comparable to those associated with reversal of vascular remodeling in animal PAH models. RVT-1201 was generally well-tolerated in both dose regimens.
- RVT-1201 has the potential to reduce serotonin production and impact vascular remodeling in PAH patients. If ultimately proven effective, the potential to dose RVT-1201 once-daily may help improve overall treatment adherence in a disease like PAH in which patients often take more than one drug in combination chronically.
- It should be understood that the foregoing description is only illustrative of the present disclosure. Various alternatives and modifications can be devised by those skilled in the art without departing from the present disclosure. Accordingly, the present disclosure is intended to embrace all such alternatives, modifications and variances which fall within the scope of the appended claims.
Claims (20)
1. A method of treating or preventing pulmonary arterial hypertension or associated pulmonary arterial hypertension in a patient comprising systemically administering to the patient a therapeutically effective amount of a compound selected from the group consisting of (i) (S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate or a pharmaceutically acceptable salt thereof, (ii) (S)-8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroeth-oxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylic acid or a pharmaceutically acceptable salt thereof, and (iii) a combination of the foregoing, wherein the therapeutically effective amount is about 1 mg/kg/day to about 50 mg/kg/day.
2. The method of claim 1 , wherein the compound or pharmaceutically acceptable salt thereof is administered orally.
3. The method of claim 2 , wherein the compound or pharmaceutically acceptable salt thereof is administered orally by a dosage form selected from the group consisting of capsules, tablets, powders, and granules.
4. The method of claim 2 , wherein the compound or pharmaceutically acceptable salt thereof is administered orally in the form of a liquid.
5. The method of claim 1 , wherein the compound or pharmaceutically acceptable salt thereof is administered one to four times per day.
6. The method of claim 1 , wherein the compound is (S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate or a pharmaceutically acceptable salt thereof.
7. The method of claim 1 , wherein the compound is (S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate.
8. The method of claim 1 , wherein the compound is (S)-8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroeth-oxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylic acid or a pharmaceutically acceptable salt thereof.
9. The method of claim 1 , wherein the compound is (S)-8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroeth-oxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylic acid.
10. The method of claim 1 , wherein the compound is in a substantially amorphous form.
11. The method of claim 1 , wherein the compound is in a substantially crystalline form.
12. The method of claim 11 , wherein the compound is a crystalline polymorph having a XRPD plot corresponding to FIG. 1 .
13. The method of claim 11 , wherein the compound is a crystalline polymorph having a XRPD plot corresponding to Table 1 or Table 2.
14. The method of claim 11 , wherein the compound is a crystalline polymorph exhibiting a characteristic XRPD peak at 19.05±0.20 (° 2θ).
15. The method of claim 1 , wherein the compound is systemically administered in the form of a composition including the compound and a pharmaceutically acceptable excipient.
16. A method of treating or preventing pulmonary arterial hypertension or associated pulmonary arterial hypertension in a patient comprising systemically administering to the patient a therapeutically effective amount of a THP1 inhibitor from about 1 mg/kg/day to about mg/kg/day.
17. A method of treating or preventing pulmonary arterial hypertension or associated pulmonary arterial hypertension in a patient comprising administering to the patient a therapeutically effective amount of a compound selected from the group consisting of (i) (S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate or a pharmaceutically acceptable salt thereof, (ii) (S)-8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroeth-oxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylic acid or a pharmaceutically acceptable salt thereof, and (iii) a combination of the foregoing, wherein the compound or pharmaceutically acceptable salt thereof is administered once per day.
18. The method of claim 17 , wherein the compound is (S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate or a pharmaceutically acceptable salt thereof.
19. The method of claim 18 , wherein the compound is a crystalline polymorph having a XRPD plot corresponding to Table 1 or Table 2.
20. The method of claim 17 , wherein the compound is (S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate or a pharmaceutically acceptable salt thereof, wherein the compound is a crystalline polymorph having a XRPD plot corresponding to FIG. 1 , wherein the therapeutically effective amount is about 1 mg/kg/day to about 50 mg/kg/day.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/149,992 US20240024316A1 (en) | 2019-03-15 | 2023-01-04 | Method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962819162P | 2019-03-15 | 2019-03-15 | |
US16/818,236 US11576915B2 (en) | 2019-03-15 | 2020-03-13 | Method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing |
US18/149,992 US20240024316A1 (en) | 2019-03-15 | 2023-01-04 | Method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/818,236 Continuation US11576915B2 (en) | 2019-03-15 | 2020-03-13 | Method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing |
Publications (1)
Publication Number | Publication Date |
---|---|
US20240024316A1 true US20240024316A1 (en) | 2024-01-25 |
Family
ID=71092560
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/818,236 Active US11576915B2 (en) | 2019-03-15 | 2020-03-13 | Method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing |
US18/149,992 Pending US20240024316A1 (en) | 2019-03-15 | 2023-01-04 | Method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/818,236 Active US11576915B2 (en) | 2019-03-15 | 2020-03-13 | Method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing |
Country Status (9)
Country | Link |
---|---|
US (2) | US11576915B2 (en) |
EP (1) | EP3938043A1 (en) |
JP (1) | JP2022525202A (en) |
KR (1) | KR20210139293A (en) |
CN (1) | CN113784717A (en) |
AU (1) | AU2020244278A1 (en) |
CA (1) | CA3133589A1 (en) |
MX (1) | MX2021011224A (en) |
WO (1) | WO2020188352A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020099926A1 (en) * | 2018-11-16 | 2020-05-22 | Altavant Sciences Gmbh | A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension |
KR20210133953A (en) * | 2019-01-30 | 2021-11-08 | 알타반트 사이언시스 게엠베하 | Dosage regimens and methods for the treatment of pulmonary arterial hypertension with rhudatristat ethyl |
CN113784717A (en) | 2019-03-15 | 2021-12-10 | 阿尔塔万特科学公司 | A method for treating pulmonary hypertension and related pulmonary hypertension and daily administration |
WO2023062595A1 (en) * | 2021-10-14 | 2023-04-20 | Altavant Sciences Gmbh | Treatment of subjects having pulmonary arterial hypertension with rodatristat ethyl |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101815534A (en) * | 2007-07-11 | 2010-08-25 | 莱西肯医药有限公司 | methods and compositions for treating pulmonary hypertension and related diseases and disorders |
UA119247C2 (en) | 2013-09-06 | 2019-05-27 | РОЙВЕНТ САЙЕНСИЗ ҐмбГ | Spirocyclic compounds as tryptophan hydroxylase inhibitors |
US9399741B2 (en) | 2013-10-09 | 2016-07-26 | Uop Llc | Methods and apparatuses for desulfurizing hydrocarbon streams |
MX2021005559A (en) * | 2018-11-14 | 2021-09-10 | Altavant Sciences Gmbh | A crystalline spirocyclic compound inhibitor of tryptophan hydroxylase 1 (tph1) for treating diseases or disorders associated with peripheral serotonin. |
WO2020099926A1 (en) | 2018-11-16 | 2020-05-22 | Altavant Sciences Gmbh | A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension |
WO2020128614A1 (en) | 2018-12-17 | 2020-06-25 | Altavant Sciences Gmbh | Method for treating interstital lung disease |
WO2020128608A1 (en) * | 2018-12-17 | 2020-06-25 | Altavant Sciences Gmbh | Compound for use in a method for treating sarcoidosis-associated pulmonary hypertension |
KR20210133953A (en) * | 2019-01-30 | 2021-11-08 | 알타반트 사이언시스 게엠베하 | Dosage regimens and methods for the treatment of pulmonary arterial hypertension with rhudatristat ethyl |
CN113784717A (en) | 2019-03-15 | 2021-12-10 | 阿尔塔万特科学公司 | A method for treating pulmonary hypertension and related pulmonary hypertension and daily administration |
-
2020
- 2020-03-13 CN CN202080033296.0A patent/CN113784717A/en active Pending
- 2020-03-13 US US16/818,236 patent/US11576915B2/en active Active
- 2020-03-13 AU AU2020244278A patent/AU2020244278A1/en not_active Abandoned
- 2020-03-13 KR KR1020217031156A patent/KR20210139293A/en unknown
- 2020-03-13 WO PCT/IB2020/000177 patent/WO2020188352A1/en active Application Filing
- 2020-03-13 JP JP2021555469A patent/JP2022525202A/en active Pending
- 2020-03-13 EP EP20732658.8A patent/EP3938043A1/en active Pending
- 2020-03-13 MX MX2021011224A patent/MX2021011224A/en unknown
- 2020-03-13 CA CA3133589A patent/CA3133589A1/en active Pending
-
2023
- 2023-01-04 US US18/149,992 patent/US20240024316A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2022525202A (en) | 2022-05-11 |
US11576915B2 (en) | 2023-02-14 |
CN113784717A (en) | 2021-12-10 |
US20200289510A1 (en) | 2020-09-17 |
AU2020244278A1 (en) | 2021-09-30 |
KR20210139293A (en) | 2021-11-22 |
CA3133589A1 (en) | 2020-09-24 |
WO2020188352A1 (en) | 2020-09-24 |
MX2021011224A (en) | 2021-12-10 |
EP3938043A1 (en) | 2022-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20240024316A1 (en) | Method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing | |
US11911382B2 (en) | Method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension | |
US20220096475A1 (en) | Method for treating sarcoidosis-associated pulmonary hypertension | |
US9522129B2 (en) | Pharmaceutical Combination | |
US8642661B2 (en) | Pharmaceutical combinations of beta-3 adrenergic receptor agonists and muscarinic receptor antagonists | |
CN109475529B (en) | Use of carbamate compounds for preventing or treating fibromyalgia or a functional syndrome associated with fibromyalgia | |
US20130172414A1 (en) | Pharmaceutical composition comprising levocarnitine and dobesilate | |
JP2015537009A (en) | Use of bucillamine in the treatment of gout | |
KR20150020160A (en) | Combination of muscarinic receptor antagonists and beta―3 adrenoceptor agonists for treating overactive bladder | |
US9271948B2 (en) | Agent for improving vesicourethral dyssynergia | |
CN112912076A (en) | Use of carbamate compounds for preventing, alleviating or treating diabetic peripheral neuropathy or chemotherapy-induced peripheral neuropathy | |
RU2774970C2 (en) | Use of carbamate compounds for prevention, relief or treatment of bipolar disorder | |
DE102004040630A1 (en) | Combination therapy with procaine | |
WO2005117853A1 (en) | Therapeutic agent for hyperlipemia and therapeutic agent for diabetes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ALTAVANT SCIENCES GMBH, SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ALONSO-GALICIA, MAGDALENA;CARPENTER, DAVID;PACK, THOMAS;AND OTHERS;REEL/FRAME:064452/0845 Effective date: 20200916 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |